“The company has hired Richard Scheller, who led drug discovery at biotech icon Genentech for 14 years before announcing he would retire in December, and who has won some of science’s top awards, including the Lasker Prize, often referred to as “America’s Nobel,” and the Kavli Prize.”
“A new class of drugs has been identified that slow the ageing process in mice, alleviating symptoms of frailty and extending a healthy lifespan.
If their effect on humans is as marked as it is on animal models, their benefit could be enormous.
The research was carried out by a team from Mayo Clinic, The Scripps Institute and other institutions and published in the journal Aging Cell yesterday.
“We view this study as a big, first step toward developing treatments that can be given safely to patients to extend healthspan or to treat age-related diseases and disorders,” said co-lead author and TSRI Professor Paul Robbins, PhD.”
Two significant news hits on Alzheimer’s recently. One team in Australia is experimenting (on mice) with ultrasound to clear up plaque buildup and the other team (in the US) is using an already approved drug commonly used to treat epilepsy to calm hyperactivity in the brain.
It was a pleasure to meet Dr. Craig Venter at Stanford this week. As you can imagine, he had strong views and a huge amount of energy. I’m super-interested in all of his work, but was surprised to find out about his efforts to fight the spread of influenza using genomics. He convinced me that it is possible to create an annual flu vaccine that actually targets the flu of that year. That would be useful.
Lots of people I know will be interested in this. Here’s the story from the researchers at Sanford-Burnham.
“We have developed a method using human pluripotent stem cells to create new cells capable of initiating human hair growth. The method is a marked improvement over current methods that rely on transplanting existing hair follicles from one part of the head to another,” said Alexey Terskikh, Ph.D., associate professor in the Development, Aging, and Regeneration Program. “Our stem cell method provides an unlimited source of cells from the patient for transplantation and isn’t limited by the availability of existing hair follicles.”
Yesterday, I visited with a bunch of scientists from UCSF’s Lim Lab. They had a cool simulation game to show how CAR-T therapy works. Essentially, you want to make your “T” cell recognize the cancer cell so it will kill it. I did it on the first try — super-fun!
“Wyss-Coray formed a start-up company, Alkahest in Menlo Park, California, and in September 2014 it began a randomized, placebo-controlled, double-blind trial at Stanford, testing the safety and efficacy of using young plasma to treat Alzheimer’s disease. Six out of a planned 18 people with Alzheimer’s, all aged 50 or above, have already begun to receive plasma harvested from men aged 30 or younger. In addition to monitoring disease symptoms, the researchers are looking for changes in brain scans and blood biomarkers of the disease.”
Here are two well-written stories about longevity, the Palo Alto Longevity Prize, and my book, 100 Plus. Journalist Joshua Alvarez did a good job interviewing a diverse set of voices. Here are the two links: one and two.
A few observations:
-Some may be surprised to see that the head of Stanford’s “Center on Longevity” says that “I’m largely on the fence about increasing lifespan. I see a real need for improving the quality of our lives and accommodating the years we’ve been given.” That’s sort of depressing, particularly given that so much of the cool tech that will extend our health is being created right at Stanford.
-I’m happy to have been given credit for writing the book that Dr. Walter Bortz, a physician who advocates for a 100 year lifespan, thought would never be written.
“Scientists have discovered an antibiotic capable of fighting infections that kill hundreds of thousands of people each year, a breakthrough that could lead to the field’s first major new drug in more than a quarter-century.”
““No, no it’s not science fiction; it’s already happening,” said Ido Bachelet to a somewhat incredulous audience member at a London event late last year. Bachelet, previously of Harvard’s Wyss Institute and faculty member at Israel’s Bar-Ilan University, is a leading figure in the field of DNA nanotechnology.
In a brief talk, Bachelet said DNA nanobots will soon be tried in a critically ill leukemia patient. The patient, who has been given roughly six months to live, will receive an injection of DNA nanobots designed to interact with and destroy leukemia cells—while causing virtually zero collateral damage in healthy tissue.
According to Bachelet, his team have successfully tested their method in cell cultures and animals and written two papers on the subject, one in Science and one in Nature.”
Some great research coming out of Stanford University. Here’s their press release, and a few news articles.
The upshot is that “Brain cells called microglia chew up toxic substances and cell debris, calm inflammation and make nerve-cell-nurturing substances. New research shows that keeping them on the job may prevent neurodegeneration.”
“We all know that exercise can make us fitter and reduce our risk for illnesses such as diabetes and heart disease. But just how, from start to finish, a run or a bike ride might translate into a healthier life has remained baffling.
Now new research reports that the answer may lie, in part, in our DNA. Exercise, a new study finds, changes the shape and functioning of our genes, an important stop on the way to improved health and fitness.”
“How old do you feel? Think carefully – the answer might help predict how much longer you’ll live. That’s according to British research posing that question to about 6,500 adults. Those who felt younger than their real age lived the longest over the following eight years.”
Here’s a list of the winners in Life Sciences. For more, see the press release.
“The 2015 Breakthrough Prizes in Life Sciences
The Breakthrough Prize in Life Sciences honors transformative advances toward understanding living systems and extending human life, with one prize dedicated to work that contributes to the understanding of Parkinson’s disease.
Alim Louis Benabid, Joseph Fourier University, for the discovery and pioneering work on the development of high-frequency deep brain stimulation (DBS), which has revolutionized the treatment of Parkinson’s disease.
C. David Allis, The Rockefeller University, for the discovery of covalent modifications of histone proteins and their critical roles in the regulation of gene expression and chromatin organization, advancing the understanding of diseases ranging from birth defects to cancer.
Victor Ambros, University of Massachusetts Medical School, and Gary Ruvkun, Massachusetts General Hospital and Harvard Medical School, for the discovery of a new world of genetic regulation by microRNAs, a class of tiny RNA molecules that inhibit translation or destabilize complementary mRNA targets. Each received a $3 million award.
Jennifer Doudna, University of California, Berkeley, Howard Hughes Medical Institute and Lawrence Berkeley National Laboratory, and Emmanuelle Charpentier, Helmholtz Center for Infection Research and Umeå University, for harnessing an ancient mechanism of bacterial immunity into a powerful and general technology for editing genomes, with wide-ranging implications across biology and medicine. Each received a $3 million award.”